Business
Why the Opthea (ASX:OPT) share price is soaring 11% today
The Opthea Ltd (ASX: OPT) share price is soaring in morning trade, up 11.36% trading at $1.72 at the time of writing.
We take a look at the ASX healthcare share’s latest drug trial announcement.
What did Opthea announce?
The Opthea share price has rocketed today after the company announced Phase 3 trials of its OPT-302 retinal disease treatment drug have started. OPT-302 is the Opthea’s “first-in-class VEGF-C/D ‘trap’ inhibitor”.
The company said it had treated its first patient, in the US state of Maryland, for neovascular age-related macular degeneration (AMD).
The clinical-stage biopharmaceutical company is conducting two simultaneous multi-centre randomised Phase 3 trials. Both clinical studies will enrol around 990…
-
General15 hours agoKununurra’s Barra Bash barramundi competition underway as restocking solution sought
-
Noosa News16 hours agoFeral pigs illegally brought into SA from NSW, DNA testing confirms
-
Noosa News20 hours agoCouncil ends water fluoridation | Noosa Today
-
General17 hours agoOne man dead another seriously injured in Morwell incident